Aisthesis Medical is transforming acute care management through early sepsis prediction
We’re thrilled to announce that Aisthesis Medical has been named one of the Top 10 Finalists in the AI-Supported Healthcare Track of the prestigious HealthTech Challengers 2024 competition!
Why This Matters
This recognition highlights the innovation and impact of our AI-powered solution, VIOSync, which is transforming acute care management through early sepsis prediction. Competing against some of the world’s most disruptive healthcare startups, being in the top 10 affirms our commitment to revolutionizing patient outcomes and advancing critical care.
What Makes Us Stand Out
Our platform, VIOSync, is designed to predict sepsis up to 48 hours in advance, allowing healthcare professionals to act sooner, reduce ICU admissions, and save lives. This achievement places us in an exclusive group of companies pushing the boundaries of health technology.
What’s Next?
As finalists, we’ll be competing in the HealthTech Challengers Grand Final, where we’ll present our cutting-edge solution to a global audience of industry leaders, healthcare professionals, and potential investors. This final stage is an incredible opportunity to showcase how VIOSync is setting new standards in predictive healthcare and to connect with partners who share our vision.
Join Us on Our Journey!
We are excited to engage with investors, clinicians, and thought leaders to explore potential collaborations and strategic partnerships as we take the next steps in scaling our impact.
Stay tuned as we prepare for the Grand Final and continue driving innovation in AI-supported healthcare solutions!
About Aisthesis Medical
Founded in 2022, Aisthesis Medical is a leading AI-driven healthcare technology company focused on enhancing clinical decision-making through advanced predictive analytics. Our flagship product, VIOSync, predicts sepsis with 97% accuracy up to 48 hours before onset, providing healthcare providers with the tools to make timely, life-saving decisions.